LVS vs PPCB · P/E 28, rev $2.90B vs P/E 0.0, $3.9M cap
Las Vegas Sands Corp (LVS) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Las Vegas Sands Corp (LVS) is a resorts & casinos company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported LVS revenue for 2024-12-31 was $2.90B. Net income was $392.0M. Revenue was up 8.0% from 2024-09-30 to 2024-12-31. LVS currently screens at market cap $35.70B and trailing P/E 28.3.
PPCB does not have a complete income-statement cache yet.
LVS currently screens at market cap $35.70B and trailing P/E 28.3. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the LVS and PPCB stock pages for the full models.
Not investment advice.